[ad_1]
- Accelerating development of the OTOF-GT and GJB2-GT gene therapy programs in collaboration with Institut Pasteur
- Advancing SENS-401 joint clinical development program with Cochlear Ltd. for hearing preservation in patients scheduled for cochlear implantation with first patient enrollment expected by mid-2022
- Sensorion will continue the proof-of-concept clinical study for Cisplatin-Induced Ototoxicity following a thorough analysis of the secondary endpoints of the AUDIBLE-S SENS-401 study
- In line with a disciplined capital allocation approach, Sensorion will explore partnering opportunities for SENS-401 in SSNHL
- Cash position of €50 million at year-end provides extended cash runway until end of Q2 2023
Regulatory News:
Sensorion ALSEN (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing disorders, announces today its full-year 2021 financial results and provides an update on its business activities and outlook for 2022.
“In 2021, Sensorion made progress across its gene therapy and small molecule programs aimed at treating hearing loss disorders,” said Nawal Ouzren, CEO of Sensorion. “We made good progress with our gene therapy programs, notably OTOF-GT for the treatment of pediatric deafness due to otoferlin deficiency and GJB2-GT for the treatment of GJB2-driven deafness in collaboration with Institut Pasteur. In parallel, we have been expanding our gene therapy CMC platform by strengthening our development lab capabilities and reinforcing our in-house expertise.
“In our small molecule portfolio, we are advancing our existing partnership with Cochlear Limited with a clinical trial of our drug candidate SENS-401 for hearing preservation in patients scheduled for cochlear implantation. We see a compelling unmet medical need and a potential clinical development pathway for SENS-401 in Cisplatin-Induced Ototoxicity…
[ad_2]
